Chronic Urticaria & Angioedema: Recent Advances

An overview of the safety and efficacy of these agents in chronic spontaneous urticaria will be presented: Barzolvolimab, Bruton tyrosine kinase (BTK) inhibitors remibrutinib and fenebrutinib, Tezepelumab and Rilzabrutinib.